MaassenVanDenBrink, Antoinette http://orcid.org/0000-0001-7176-126X
Terwindt, Gisela M.
Cohen, Joshua M.
Barash, Steve
Campos, Verena Ramirez
Galic, Maja
Ning, Xiaoping
Kärppä, Mikko
Funding for this research was provided by:
Teva Branded Pharmaceutical Products R&D, Inc.
Article History
Received: 31 May 2021
Accepted: 26 September 2021
First Online: 18 December 2021
Declarations
:
: The FOCUS study was conducted in full accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guidelines for Good Clinical Practice and all applicable national and local laws and regulations. All participants provided written informed consent prior to participation in the study. The study protocol and consent form were reviewed and approved by the relevant independent ethics committee or institutional review board at participating study sites.
: Not applicable.
: Antoinette MaassenVanDenBrink: Research/consultancy/speaker support from Allergan, Amgen/Novartis, Lilly, and Teva; independent support from the Dutch Research Council and the Dutch Heart and Brain Foundations.Gisela M. Terwindt: Consultancy support from Novartis, Allergan, Lilly, and Teva; independent support from the Dutch Organization for Scientific Research, the Dutch Heart & Brain Foundations, the International Retinal Research Foundation, and Dioraphte.Joshua M. Cohen: Employee and/or stockholder of Teva Branded Pharmaceutical Products R&D, Inc.Steve Barash: Employee and/or stockholder of Teva Branded Pharmaceutical Products R&D, Inc.Verena Ramirez Campos: Employee and/or stockholder of Teva Branded Pharmaceutical Products R&D, Inc.Maja Galic: Employee and/or stockholder of Teva Branded Pharmaceutical Products R&D, Inc.Xiaoping Ning: Employee and/or stockholder of Teva Branded Pharmaceutical Products R&D, Inc.Mikko Kärppä: Received research compensation from Teva and Amgen.